| HOME >> BIOLOGY >> TECHNOLOGY |
In millions, except per share data
GAAP results $(272) $(0.18) $76 $0.05
Non-GAAP adjustments:
Acquisition and divestiture
related charges 435 0.29 77 0.05
Amortization expense 136 0.09 (1) 118 0.08
Adjusted results $299 $0.20 (1) $271 0.18
(1) Calculated by assuming stock-based dilution of 12.5 million shares
Three Months Ended
September 30,
2007 2006
Acquisition and divestiture related
charges:
Loss on assets held for sale $352
Purchased research and development 75
Integration costs (a) 10 $9
Step-up value of inventory sold (b) 94
Fair-value adjustment for the sharing
of proceeds feature of the Abbott
Laboratories stock purchase (c) 13
CRM technology offering charge (b) 31
437 147
Income tax benefit (d) (2) (70)
Acquisition and divestiture related
charges, net of tax $435 $77
Amortization expense:
Amortization expense $155 $153
Income tax benefit (d) (19) (35)
Amortization expense, net of tax $136 $118
(a) Recorded $8 million in 2007 to selling, general and administrative
expens
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2007 PR Newswire. All rights reserved |